AbbVie's investigational obesity drug shows up to 9.8% weight loss in Phase 1 trial
AbbVie (ABBV) reported promising results from the Phase 1 clinical trial of its experimental long-acting amylin analog, ABBV-295, for treating obesity. The data showed that patients experienced body weight reductions ranging between -7.8% and -9.8% at Week 12 when administered once-weekly doses. These results highlight the potential efficacy of ABBV-295 as a treatment option in an expanding market for obesity therapies, particularly with growing interest in long-acting formulations that improve patient compliance. The findings could position AbbVie to advance this drug into later-stage trials and potentially compete more effectively within the pharmaceutical sector. The announcement is likely to be viewed positively by investors due to its implications for future revenue streams from a new obesity treatment, especially as demand increases in response to rising global health concerns around metabolic diseases.
Tickers: $ABBV